SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients.
Identifieur interne : 000354 ( Main/Curation ); précédent : 000353; suivant : 000355SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients.
Auteurs : Roberto Gozalbo-Rovira [Espagne] ; Estela Gimenez [Espagne] ; Víctor Latorre [Espagne] ; Clara Francés-G Mez [Espagne] ; Eliseo Albert [Espagne] ; Javier Buesa [Espagne] ; Alberto Marina [Espagne] ; María Luisa Blasco [Espagne] ; Jaime Signes-Costa [Espagne] ; Jesús Rodríguez-Díaz [Espagne] ; Ron Geller [Espagne] ; David Navarro [Espagne]Source :
- Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [ 1873-5967 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Anticorps antiviraux (sang), Anticorps neutralisants (sang), Betacoronavirus (MeSH), Femelle (MeSH), Glycoprotéine de spicule des coronavirus (immunologie), Hospitalisation (statistiques et données numériques), Humains (MeSH), Indice de gravité de la maladie (MeSH), Infections à coronavirus (immunologie), Infections à coronavirus (sang), Inflammation (sang), Inflammation (virologie), Jeune adulte (MeSH), Marqueurs biologiques (sang), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (immunologie), Pneumopathie virale (sang), Sites de fixation des anticorps (MeSH), Sujet âgé (MeSH), Études rétrospectives (MeSH).
- MESH :
- immunologie : Glycoprotéine de spicule des coronavirus, Infections à coronavirus, Pneumopathie virale.
- sang : Anticorps antiviraux, Anticorps neutralisants, Infections à coronavirus, Inflammation, Marqueurs biologiques, Pneumopathie virale.
- statistiques et données numériques : Hospitalisation.
- virologie : Inflammation.
- Adulte, Adulte d'âge moyen, Betacoronavirus, Femelle, Humains, Indice de gravité de la maladie, Jeune adulte, Mâle, Pandémies, Sites de fixation des anticorps, Sujet âgé, Études rétrospectives.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Betacoronavirus (MeSH), Binding Sites, Antibody (MeSH), Biomarkers (blood), Coronavirus Infections (blood), Coronavirus Infections (immunology), Female (MeSH), Hospitalization (statistics & numerical data), Humans (MeSH), Inflammation (blood), Inflammation (virology), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (blood), Pneumonia, Viral (immunology), Retrospective Studies (MeSH), Severity of Illness Index (MeSH), Spike Glycoprotein, Coronavirus (immunology), Young Adult (MeSH).
- MESH :
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral, Biomarkers.
- blood : Coronavirus Infections, Inflammation, Pneumonia, Viral.
- immunology : Coronavirus Infections, Pneumonia, Viral, Spike Glycoprotein, Coronavirus.
- statistics & numerical data : Hospitalization.
- virology : Inflammation.
- Adult, Aged, Betacoronavirus, Binding Sites, Antibody, Female, Humans, Male, Middle Aged, Pandemics, Retrospective Studies, Severity of Illness Index, Young Adult.
Abstract
BACKGROUND
The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity.
PATIENTS AND METHODS
This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers were measured in a GFP reporterbased pseudotyped virus platform. Demographic and clinical data, complete blood counts, as well as serum levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and interleukin-6 (IL-6) were retrieved from clinical charts.
RESULTS
The overall correlation between levels of both antibody measurements was good (Rho = 0.82; P = 0 < 0.001). SARS-CoV-2 RBD IgG and NtAb50 levels in sera collected up to day 30 after the onset of symptoms were comparable between ICU and non-ICU patients (P=>0.1). Four ICU patients died; two of these achieved NtAb50 titers ≥1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0-<0.2) or weak (Rho=>0.2-<0.4) correlations were observed between anti-RBD IgGs, NtAb50, and serum levels pro-inflammatory biomarkers.
CONCLUSIONS
The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50 levels and COVID-19 severity.
DOI: 10.1016/j.jcv.2020.104611
PubMed: 32882666
PubMed Central: PMC7459327
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000354
Links to Exploration step
pubmed:32882666Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients.</title><author><name sortKey="Gozalbo Rovira, Roberto" sort="Gozalbo Rovira, Roberto" uniqKey="Gozalbo Rovira R" first="Roberto" last="Gozalbo-Rovira">Roberto Gozalbo-Rovira</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Microbiology, School of Medicine, University of Valencia, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Gimenez, Estela" sort="Gimenez, Estela" uniqKey="Gimenez E" first="Estela" last="Gimenez">Estela Gimenez</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Latorre, Victor" sort="Latorre, Victor" uniqKey="Latorre V" first="Víctor" last="Latorre">Víctor Latorre</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Frances G Mez, Clara" sort="Frances G Mez, Clara" uniqKey="Frances G Mez C" first="Clara" last="Francés-G Mez">Clara Francés-G Mez</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Albert, Eliseo" sort="Albert, Eliseo" uniqKey="Albert E" first="Eliseo" last="Albert">Eliseo Albert</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Buesa, Javier" sort="Buesa, Javier" uniqKey="Buesa J" first="Javier" last="Buesa">Javier Buesa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Marina, Alberto" sort="Marina, Alberto" uniqKey="Marina A" first="Alberto" last="Marina">Alberto Marina</name><affiliation wicri:level="1"><nlm:affiliation>Department of Genomics and Proteomics, Instituto de Biomedicina de Valencia (IBV-CSIC) and CIBER de Enfermedades Raras (CIBERER-ISCIII), Valencia, Spain; Decoy-SARS-CoV-2 Study Group from the Institute of Biomedicine of Valencia (Group Members List in Acknowledgements Section), Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Genomics and Proteomics, Instituto de Biomedicina de Valencia (IBV-CSIC) and CIBER de Enfermedades Raras (CIBERER-ISCIII), Valencia, Spain; Decoy-SARS-CoV-2 Study Group from the Institute of Biomedicine of Valencia (Group Members List in Acknowledgements Section)</wicri:regionArea></affiliation></author><author><name sortKey="Blasco, Maria Luisa" sort="Blasco, Maria Luisa" uniqKey="Blasco M" first="María Luisa" last="Blasco">María Luisa Blasco</name><affiliation wicri:level="1"><nlm:affiliation>Medical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Signes Costa, Jaime" sort="Signes Costa, Jaime" uniqKey="Signes Costa J" first="Jaime" last="Signes-Costa">Jaime Signes-Costa</name><affiliation wicri:level="1"><nlm:affiliation>Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Rodriguez Diaz, Jesus" sort="Rodriguez Diaz, Jesus" uniqKey="Rodriguez Diaz J" first="Jesús" last="Rodríguez-Díaz">Jesús Rodríguez-Díaz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain. Electronic address: jesus.rodriguez@uv.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Microbiology, School of Medicine, University of Valencia, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Geller, Ron" sort="Geller, Ron" uniqKey="Geller R" first="Ron" last="Geller">Ron Geller</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain. Electronic address: ron.geller@uv.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Navarro, David" sort="Navarro, David" uniqKey="Navarro D" first="David" last="Navarro">David Navarro</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. Electronic address: david.navarro@uv.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32882666</idno><idno type="pmid">32882666</idno><idno type="doi">10.1016/j.jcv.2020.104611</idno><idno type="pmc">PMC7459327</idno><idno type="wicri:Area/Main/Corpus">000354</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000354</idno><idno type="wicri:Area/Main/Curation">000354</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000354</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients.</title><author><name sortKey="Gozalbo Rovira, Roberto" sort="Gozalbo Rovira, Roberto" uniqKey="Gozalbo Rovira R" first="Roberto" last="Gozalbo-Rovira">Roberto Gozalbo-Rovira</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Microbiology, School of Medicine, University of Valencia, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Gimenez, Estela" sort="Gimenez, Estela" uniqKey="Gimenez E" first="Estela" last="Gimenez">Estela Gimenez</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Latorre, Victor" sort="Latorre, Victor" uniqKey="Latorre V" first="Víctor" last="Latorre">Víctor Latorre</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Frances G Mez, Clara" sort="Frances G Mez, Clara" uniqKey="Frances G Mez C" first="Clara" last="Francés-G Mez">Clara Francés-G Mez</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Albert, Eliseo" sort="Albert, Eliseo" uniqKey="Albert E" first="Eliseo" last="Albert">Eliseo Albert</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Buesa, Javier" sort="Buesa, Javier" uniqKey="Buesa J" first="Javier" last="Buesa">Javier Buesa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Marina, Alberto" sort="Marina, Alberto" uniqKey="Marina A" first="Alberto" last="Marina">Alberto Marina</name><affiliation wicri:level="1"><nlm:affiliation>Department of Genomics and Proteomics, Instituto de Biomedicina de Valencia (IBV-CSIC) and CIBER de Enfermedades Raras (CIBERER-ISCIII), Valencia, Spain; Decoy-SARS-CoV-2 Study Group from the Institute of Biomedicine of Valencia (Group Members List in Acknowledgements Section), Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Genomics and Proteomics, Instituto de Biomedicina de Valencia (IBV-CSIC) and CIBER de Enfermedades Raras (CIBERER-ISCIII), Valencia, Spain; Decoy-SARS-CoV-2 Study Group from the Institute of Biomedicine of Valencia (Group Members List in Acknowledgements Section)</wicri:regionArea></affiliation></author><author><name sortKey="Blasco, Maria Luisa" sort="Blasco, Maria Luisa" uniqKey="Blasco M" first="María Luisa" last="Blasco">María Luisa Blasco</name><affiliation wicri:level="1"><nlm:affiliation>Medical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Signes Costa, Jaime" sort="Signes Costa, Jaime" uniqKey="Signes Costa J" first="Jaime" last="Signes-Costa">Jaime Signes-Costa</name><affiliation wicri:level="1"><nlm:affiliation>Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Rodriguez Diaz, Jesus" sort="Rodriguez Diaz, Jesus" uniqKey="Rodriguez Diaz J" first="Jesús" last="Rodríguez-Díaz">Jesús Rodríguez-Díaz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain. Electronic address: jesus.rodriguez@uv.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Microbiology, School of Medicine, University of Valencia, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Geller, Ron" sort="Geller, Ron" uniqKey="Geller R" first="Ron" last="Geller">Ron Geller</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain. Electronic address: ron.geller@uv.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia</wicri:regionArea></affiliation></author><author><name sortKey="Navarro, David" sort="Navarro, David" uniqKey="Navarro D" first="David" last="Navarro">David Navarro</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. Electronic address: david.navarro@uv.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</title><idno type="eISSN">1873-5967</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Betacoronavirus (MeSH)</term><term>Binding Sites, Antibody (MeSH)</term><term>Biomarkers (blood)</term><term>Coronavirus Infections (blood)</term><term>Coronavirus Infections (immunology)</term><term>Female (MeSH)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Inflammation (blood)</term><term>Inflammation (virology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (blood)</term><term>Pneumonia, Viral (immunology)</term><term>Retrospective Studies (MeSH)</term><term>Severity of Illness Index (MeSH)</term><term>Spike Glycoprotein, Coronavirus (immunology)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Anticorps antiviraux (sang)</term><term>Anticorps neutralisants (sang)</term><term>Betacoronavirus (MeSH)</term><term>Femelle (MeSH)</term><term>Glycoprotéine de spicule des coronavirus (immunologie)</term><term>Hospitalisation (statistiques et données numériques)</term><term>Humains (MeSH)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (sang)</term><term>Inflammation (sang)</term><term>Inflammation (virologie)</term><term>Jeune adulte (MeSH)</term><term>Marqueurs biologiques (sang)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (immunologie)</term><term>Pneumopathie virale (sang)</term><term>Sites de fixation des anticorps (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Biomarkers</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Coronavirus Infections</term><term>Inflammation</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term><term>Infections à coronavirus</term><term>Inflammation</term><term>Marqueurs biologiques</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Hospitalisation</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Inflammation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Betacoronavirus</term><term>Binding Sites, Antibody</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Betacoronavirus</term><term>Femelle</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Jeune adulte</term><term>Mâle</term><term>Pandémies</term><term>Sites de fixation des anticorps</term><term>Sujet âgé</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity.</p></div><div type="abstract" xml:lang="en"><p><b>PATIENTS AND METHODS</b></p><p>This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers were measured in a GFP reporterbased pseudotyped virus platform. Demographic and clinical data, complete blood counts, as well as serum levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and interleukin-6 (IL-6) were retrieved from clinical charts.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The overall correlation between levels of both antibody measurements was good (Rho = 0.82; P = 0 < 0.001). SARS-CoV-2 RBD IgG and NtAb50 levels in sera collected up to day 30 after the onset of symptoms were comparable between ICU and non-ICU patients (P=>0.1). Four ICU patients died; two of these achieved NtAb50 titers ≥1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0-<0.2) or weak (Rho=>0.2-<0.4) correlations were observed between anti-RBD IgGs, NtAb50, and serum levels pro-inflammatory biomarkers.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50 levels and COVID-19 severity.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32882666</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5967</ISSN><JournalIssue CitedMedium="Internet"><Volume>131</Volume><PubDate><Year>2020</Year><Month>10</Month></PubDate></JournalIssue><Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title><ISOAbbreviation>J Clin Virol</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients.</ArticleTitle><Pagination><MedlinePgn>104611</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1386-6532(20)30353-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcv.2020.104611</ELocationID><Abstract><AbstractText Label="BACKGROUND">The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity.</AbstractText><AbstractText Label="PATIENTS AND METHODS">This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers were measured in a GFP reporterbased pseudotyped virus platform. Demographic and clinical data, complete blood counts, as well as serum levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and interleukin-6 (IL-6) were retrieved from clinical charts.</AbstractText><AbstractText Label="RESULTS">The overall correlation between levels of both antibody measurements was good (Rho = 0.82; P = 0 < 0.001). SARS-CoV-2 RBD IgG and NtAb50 levels in sera collected up to day 30 after the onset of symptoms were comparable between ICU and non-ICU patients (P=>0.1). Four ICU patients died; two of these achieved NtAb50 titers ≥1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0-<0.2) or weak (Rho=>0.2-<0.4) correlations were observed between anti-RBD IgGs, NtAb50, and serum levels pro-inflammatory biomarkers.</AbstractText><AbstractText Label="CONCLUSIONS">The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50 levels and COVID-19 severity.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gozalbo-Rovira</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gimenez</LastName><ForeName>Estela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latorre</LastName><ForeName>Víctor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francés-Gómez</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Eliseo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buesa</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marina</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Genomics and Proteomics, Instituto de Biomedicina de Valencia (IBV-CSIC) and CIBER de Enfermedades Raras (CIBERER-ISCIII), Valencia, Spain; Decoy-SARS-CoV-2 Study Group from the Institute of Biomedicine of Valencia (Group Members List in Acknowledgements Section), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>María Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Medical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Signes-Costa</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodríguez-Díaz</LastName><ForeName>Jesús</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain. Electronic address: jesus.rodriguez@uv.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geller</LastName><ForeName>Ron</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain. Electronic address: ron.geller@uv.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. Electronic address: david.navarro@uv.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Virol</MedlineTA><NlmUniqueID>9815671</NlmUniqueID><ISSNLinking>1386-6532</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001666" MajorTopicYN="N">Binding Sites, Antibody</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Inflammatory biomarkers</Keyword><Keyword MajorTopicYN="Y">Neutralizing antibodies</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>08</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32882666</ArticleId><ArticleId IdType="pii">S1386-6532(20)30353-X</ArticleId><ArticleId IdType="doi">10.1016/j.jcv.2020.104611</ArticleId><ArticleId IdType="pmc">PMC7459327</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000354 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000354 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:32882666
|texte= SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32882666" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |